Clinical Trial Update: FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the FXR agonist obeticholic acid for severe alcohol-associated hepatitis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol-associated Hepatitis

Drugs mentioned

• Ocaliva (obeticholic acid)

Snippet

Sponsor: Intercept Pharmaceuticals | Conditions: Alcohol Associated Hepatitis | Phase 2 | Status: TERMINATED